Urinary Bladder Neoplasms: all 1,649 studies

Page 1 of 17. Open to participants first (427), then studies with results posted, then the rest; newest registration first within each.

• Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin IdentificationRecruitingNCT07888374
• Phase I Study of Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy FailureRecruitingNCT07881666Phase 1
• The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder CancerNot yet recruitingNCT07873333Not applicable
• BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyRecruitingNCT07869836Phase 3
• DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerNot yet recruitingNCT07853053Phase 1
• Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder SamplesRecruitingNCT07848854Phase 2
• A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)Not yet recruitingNCT07829783Phase 3
• A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial CancerNot yet recruitingNCT07827612Phase 2
• Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)RecruitingNCT07820566
• Feasibility of HISA During TURBT for NMIBCNot yet recruitingNCT07817173Not applicable
• Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBTNot yet recruitingNCT07808216Phase 2
• A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder CancerRecruitingNCT07804056Phase 3
• Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder CancerNot yet recruitingNCT07800507Phase 1/2
• Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)Not yet recruitingNCT07795255Phase 3
• TR115 in ARID1A-Mutated Advanced Solid TumorsNot yet recruitingNCT07793318Phase 2
• A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in PortugalRecruitingNCT07784387
• A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG FailureNot yet recruitingNCT07783815Phase 1
• Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)RecruitingNCT07782164
• Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With CancerNot yet recruitingNCT07781852Early Phase 1
• REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder TumorsNot yet recruitingNCT07762820Not applicable
• Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)RecruitingNCT07762586Phase 2
• Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder CancerNot yet recruitingNCT07756008Phase 2/3
• Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBCRecruitingNCT07749924Not applicable
• Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment RecommendationsRecruitingNCT07739121
• A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in KoreaNot yet recruitingNCT07735793
• Analysis of Breath Volatile Organic Compounds Using Mass SpectrometryNot yet recruitingNCT07732686
• LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the BladderRecruitingNCT07728474Not applicable
• AI-Guided TURBT for Bladder CancerNot yet recruitingNCT07727343Not applicable
• Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER TrialRecruitingNCT07726602
• Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBCNot yet recruitingNCT07724886Not applicable
• Development of an AI-Agent for Urological Disease Diagnosis and TreatmentRecruitingNCT07721935
• An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingNCT07720284Phase 3
• Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingNCT07717242Phase 2
• PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder CancerNot yet recruitingNCT07690878Phase 2
• Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid TumorsAvailableNCT07675057
• Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder CancerRecruitingNCT07673016
• Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingNCT07667335Phase 1/2
• Imaging Study of [89Zr]DFO-YS5 for Cancer DetectionRecruitingNCT07664397Phase 1
• Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)Not yet recruitingNCT07662863Phase 2
• Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruitingNCT07660055Phase 1
• A Study of a Side Effects and Resource Navigation Program for People With CancerRecruitingNCT07646847Not applicable
• Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial CarcinomaNot yet recruitingNCT07643519Phase 2
• Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial CarcinomaNot yet recruitingNCT07639983Phase 2
• Prehabilitation in High-risk Oncologic SurgeryRecruitingNCT07638410Not applicable
• Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma DiagnosisRecruitingNCT07614594
• HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBCNot yet recruitingNCT07608224Phase 2/3
• Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer StagingRecruitingNCT07602010
• Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBTRecruitingNCT07589413
• T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder CancerRecruitingNCT07581496
• Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE TrialRecruitingNCT07579195Phase 1/2
• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 3
• Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response TrialNot yet recruitingNCT07555769Phase 1
• An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language ModelsNot yet recruitingNCT07555756Not applicable
• Acupuncture and Exercise for EV-Pembro-Induced Peripheral NeuropathyRecruitingNCT07548476Not applicable
• Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor MuscleRecruitingNCT07545694
• Tumor Budding and T1 Substaging in Urothelial Bladder CancerNot yet recruitingNCT07529639
• Immune-Stromal Landscape in Muscle-Invasive Bladder CancerNot yet recruitingNCT07525349
• Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative TreatmentRecruitingNCT07524426Not applicable
• Detecting CREPT in Urine for Bladder Cancer Diagnosis and MonitoringRecruitingNCT07514897
• Bladder EpiCheck Product Development StudyRecruitingNCT07514143
• Outcomes of Definitive Radiotherapy for Bladder CancerNot yet recruitingNCT07503795
• Early vs Delayed Intravesical Blad-Care During BCG TherapyRecruitingNCT07495072Not applicable
• Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial CarcinomaRecruitingNCT07492628Phase 1
• Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerRecruitingNCT07480356Phase 3
• Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT07475403Phase 2
• Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder CancerNot yet recruitingNCT07468838
• A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerNot yet recruitingNCT07464145Phase 3
• Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract Infections Prevention: a Non-inferiority Randomized Controlled TrialRecruitingNCT07463963Not applicable
• Multiplex Mutation Detection Using Mass Spectrometry in Bladder CancerRecruitingNCT07424560
• Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingNCT07421700Phase 1/2
• Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder CancerRecruitingNCT07420517Phase 2
• A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingNCT07419295Phase 3
• Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomARecruitingNCT07413523Not applicable
• EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid TumorsRecruitingNCT07410676Phase 1/2
• VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder TumorsNot yet recruitingNCT07408830Not applicable
• INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)RecruitingNCT07403630Not applicable
• A Study of Ward Admissions for HaematuriaRecruitingNCT07395037
• Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid TechnologyRecruitingNCT07379281
• Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.RecruitingNCT07379268
• Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.RecruitingNCT07379255
• Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)RecruitingNCT07359235Phase 1
• SL-28 for Advanced Solid TumoursRecruitingNCT07341737Phase 1/2
• Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyRecruitingNCT07339761Not applicable
• A First in Human Study of PLT012 in Participants With Solid Tumor CancersRecruitingNCT07337525Phase 1
• Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingNCT07332351Phase 2
• Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)RecruitingNCT07327489
• Adaptive Radiotherapy for Genitourinary CancersRecruitingNCT07324798Not applicable
• Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBCRecruitingNCT07322263Phase 2
• Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery ExplorationRecruitingNCT07307456Phase 2
• Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER TrialRecruitingNCT07302230Not applicable
• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsRecruitingNCT07277413Phase 1
• Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder CancerNot yet recruitingNCT07261592Phase 1/2
• Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)Not yet recruitingNCT07260162Phase 1
• The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE TrialNot yet recruitingNCT07257718Phase 2
• Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical CystectomyRecruitingNCT07234968Not applicable
• KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)RecruitingNCT07232602Phase 1/2
• Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC PatientsNot yet recruitingNCT07231809Not applicable
• Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialRecruitingNCT07227077Not applicable
• Home Intravenous Fluid Infusion After Undergoing Radical CystectomyRecruitingNCT07225205Not applicable

← Urinary Bladder Neoplasms overview